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Macrolide antibiotics such as erythromycin are clinically important polyketide natural products. We have engineered a
recombinant strain of Escherichia coli that produces small but measurable quantities of the bioactive macrolide 6-
deoxyerythromycin D. Bioassay-guided evolution of this strain led to the identification of an antibiotic-overproducing
mutation in the mycarose biosynthesis and transfer pathway that was detectable via a colony-based screening assay.
This high-throughput assay was then used to evolve second-generation mutants capable of enhanced precursor-
directed biosynthesis of macrolide antibiotics. The availability of a screen for macrolide biosynthesis in E. coli offers a
fundamentally new approach in dissecting modular megasynthase mechanisms as well as engineering antibiotics with
novel pharmacological properties.
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Introduction
Polyketides are a diverse and clinically important class of
natural products which exhibit anti-infective, antitumor,
immunosuppressive, and cholesterol-lowering properties,
among others [1]. The modular architecture of polyketide
synthases provides an attractive scaffold for biosynthetic
engineering [2]. However, many natural products from this
family require post–polyketide synthase modiﬁcations, in-
cluding glycosylation, alkylation, and oxidation/reduction, to
be fully active [3]. For example, glycosylation plays a critical
role in the activity of macrolide antibacterial agents, such as
erythromycin. Reconstitution of glycosylation pathways from
soil bacteria into heterologous hosts requires the horizontal
transfer of genes that encode nucleoside diphosphate (NDP)
sugar biosynthesis, including aminosugars and deoxysugars,
as well as appropriate glycosyl transferases capable of
ligating these activated sugars to acceptor substrates. Because
of these challenges, there are very few examples of
reconstitution of glycosylation pathways in heterologous
hosts [4–6]. In Escherichia coli, for example, glycosylation
efﬁciency is low [7].
Earlier work from our laboratory led to the reconstitution
of the deoxyerythronolide B synthase (DEBS) pathway in E.
coli, resulting in substantial production of the aglycone 6-
deoxyerythronolide B (6dEB; ; 200 mg/l) [8]. The antibiotic
erythromycin D, however, bears two deoxysugars, desos-
amine and mycarose, both of which are crucial for high
antibacterial activity. Here, we describe the coexpression of
both the glycosylation pathways and DEBS, resulting in
successful production of biologically active 6-deoxyerythro-
mycin D (6d-EryD) in E. coli BAP1 (Figure 1A). The
reconstitution of erythromycin biosynthesis in E. coli
provides a unique opportunity for a genetics-led approach
to biosynthetic engineering. As a ﬁrst step toward realizing
this potential, an activity-based screening assay was devel-
oped. Initial applications of this high-throughput assay are
also described.
Results/Discussion
Reconstitution of TDP-Desosamine Biosynthesis and
Glycosyl Transfer
The aminosugar desosamine plays a critical role in
macrolide activity as evidenced by oleandomycin, pikromy-
cin, narbomycin, tylosin, and erythromycin antibiotics [9].
Speciﬁcally, it promotes ribosomal binding through a
combination of hydrogen bonding and electrostatic inter-
actions [10]. The biosynthesis of thymidine diphosphate
(TDP)-D-desosamine (E) (Figure 1B) requires the activation
of D-glucose-1-phosphate to TDP-D-glucose (A) by TDP-D-
glucose synthetase, followed by dehydration at C4 and C6 via
TDP-D-glucose 4,6-dehydratase [11]. Due to its high expres-
sion levels in E. coli, TylAI, a TDP-glucose synthetase from the
tylosin gene cluster in Streptomyces fradiae [12–14], was
recruited for desosamine generation. For similar reasons,
DesIV, encoded by the pikromycin gene cluster from S.
venezuelae, was used as the TDP-glucose 4,6-dehydratase [11].
When expressed in E. coli, these two proteins produced the
expected TDP-4-keto-6-deoxy-glucose (B) from glucose-1-
phosphate [11], as veriﬁed by high-performance liquid
chromatography analysis in the in vitro assay (Figure S7).
The pikromycin biosynthetic enzymes, DesI and DesII,
were used to catalyze C4-deoxygenation and C3-oxidation of
TDP-4-keto-6-deoxy-D-glucose (B) [11,15]. DesI, a pyridox-
amine-5-phosphate–dependent 4-aminotransferase, converts
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PLoS BIOLOGYTDP-4-keto-6-deoxy-D-glucose (B) into TDP-4-amino-6-de-
oxy-D-glucose. DesII, a member of the radical S-adenosylme-
thionine (SAM) superfamily, harbors a [4Fe-4S] cluster that
carries out the C4 deamination of TDP-4-amino-6-deoxy-D-
glucose to produce TDP-3-keto-4,6-dideoxy-D-glucose (C)
[11,16]. Therefore, we coexpressed the ﬂavodoxin and
ﬂavodoxin reductase genes from E. coli as an additional
electron carrier system [17,18], which resulted in increased
DesI/DesII activity in vivo (as judged by complementation
experiments; data not shown). The ﬁnal steps of TDP-D-
desosamine biosynthesis in E. coli are catalyzed by DesV, an
aminotransferase catalyzing the conversion of intermediate
TDP-3-keto-4,6-dideoxy-D-glucose (C) to TDP-3-amino-4,6-
dideoxy-D-glucose (D) [19], and DesVI, a S-adenosylmethio-
nine–dependent N,N9-dimethylase acting on the C3 amino
group of TDP-3-amino-4,6-dideoxy-D-glucose (D) [20].
Once TDP-D-desosamine (E) is synthesized in vivo, it must
be transferred to the acceptor substrate by an appropriate
glycosyl transferase. Glycosyl transferases play important
roles in a variety of biological processes, including cell wall
biosynthesis, signal transduction, and macrolide biosynthesis
[21]. Two desosaminyl transferase genes, eryCIII and desVII,
that have been functionally expressed in E. coli [22–24], were
evaluated. EryCIII, a desosaminyl transferase from Saccharo-
polyspora erythraea [22,23], catalyzes the attachment of desos-
amine to a-mycarosyl-erythronolide B (aMEB). The activity of
this highly selective transferase increases dramatically in the
presence of EryCII [23]. DesVII from S. venezuelae [25] also
requires a chaperone protein, DesVIII, for full activity [24],
but unlike EryCIII, it displays broad substrate tolerance for
both aglycones [25] as well as TDP-sugar substrates [26].
However, since EryCII/EryCIII are more efﬁcient in accepting
the substrate of interest, aMEB, than DesVII/DesVIII (data not
shown), eryCII and eryCIII were combined with the above
desosamine biosynthetic genes on a single expression
plasmid, pHL74 (Cm
R) or, alternatively, pHL50 (Kan
R) (Figure
1B and Table 1).
Reconstitution of TDP-Mycarose Biosynthesis and Transfer
Mycarose is a common 2,6-deoxysugar found in polyketide
compounds and contributes signiﬁcantly to the high anti-
bacterial activity of erythromycin. For example, desosaminyl
clarithronolide, which lacks a mycarose substituent, has less
than 2% of the activity of erythromycin D against Bacillus
subtilis (unpublished data). Therefore, to synthesize fully
active erythromycin analogs, we reconstituted an optimal
set of TDP-L-mycarose biosynthetic genes from the homol-
ogous erythromycin and tylosin biosynthetic gene clusters
(Figure 1C).
The ﬁrst two steps from glucose-1-phosphate to 4-keto-6-
deoxy-D-glucose (B) [12] are shared with the TDP-D-desos-
amine biosynthetic pathway. To synthesize TDP-L-mycarose
(K) from TDP-4-keto-6-deoxy-D-glucose (B), a synthetic
operon comprised of the eryBVI, eryBII, tylCIII, tylCVII, and
eryBIV genes was constructed (pHL71; Table 1). The eryBV
mycarosyl transferase gene was also included in this operon.
Again, genes from the tylosin pathway were harnessed from
sources that expressed well in E. coli. EryBVI and EryBII,
which catalyze C2-deoxygenation of TDP-4-keto-6-deoxy-D-
glucose (B) to yield TDP-4-keto-2,6-dideoxy-D-glucose (H),
Figure 1. Production of 6d-EryD in E. coli
(A) Biosynthesis of 6d-EryD in E. coli BAP1. (*mmCoA, methylmalonyl-
CoA).
(B) Reconstitution of the TDP-desosamine biosynthesis and transfer
pathway (pHL74, pHL50). A, TDP-D-glucose; B, TDP-4-keto-6-deoxy-D-
glucose; C, TDP-3-keto-4,6-dideoxy-D-glucose; D, TDP-3-amino-4,6-di-
deoxy-D-glucose; E, TDP-D-desosamine; F, R¼OH, erythromycin D, R¼H,
6-deoxyerythromycin D.
(C) Reconstitution of the TDP-mycarose biosynthesis and transfer
pathway (pHL80, pHL71). G, TDP-3,4-diketo-2,6-dideoxy-D-glucose; H,
TDP-4-keto-2,6-dideoxy-D-glucose; I, TDP-4-keto-3-methyl-2,6-dideoxy-
D-glucose; J, TDP-4-keto-3-methyl-2,6-dideoxy-L-glucose; K, TDP–L-my-
carose; L, aMEB.
doi:10.1371/journal.pbio.0050045.g001
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Author Summary
The antibacterial activity of erythromycin, an important polyketide
antibiotic precursor, requires the transfer of two unusual sugars
called mycarose and desosamine (both glycosyl groups), onto the
nonsugar part of the glycoside molecule (macrocyclic aglycone). We
reconstituted the biosynthetic pathways of both sugars in
Escherichia coli to yield the 6-deoxyerythromycin D antibiotic. By
engineering a recombinant strain of E. coli that produces the
bioactive macrolide 6-deoxyerythromycin D from propionate, we
have developed a fundamentally new tool for enhancing the
efficiency of biosynthetic engineering of this class of antibiotics.
Initially, this recombinant strain produced barely enough antibiotic
activity to establish an activity-based screening assay. We therefore
used the assay to screen for antibiotic overproducers. After three
rounds of screening, we identified E. coli cells that overproduced the
6-deoxyerythromycin D antibiotic with significant modifications in
the mycarose biosynthetic pathway. We used the same activity-
based screening system to evolve E. coli mutants capable of more
efficient precursor-directed biosynthesis. As the first example of
bioassay-guided evolution of an antibiotic pathway in E. coli, these
results open the door for harnessing the power of genetics for
mechanistic investigations into polyketide synthases and also for
biosynthetic engineering.are structurally and functionally distinct from the corre-
sponding enzymes catalyzing the C-3 deoxygenation in the
biosynthesis of 3,6-dideoxysugars [27]. TylCIII, a 46.4-kDa C-
methyl transferase, catalyzes C-3 methylation of the 2,6-
dideoxysugar (H) to produce TDP-4-keto-3-methyl-2,6-di-
deoxy-D-glucose (I), and uses S-AdoMet as a cosubstrate
[28]. C5-epimerization is catalyzed by TylCVII [29], whereas
EryBIV, a 4-ketoreductase, converts TDP-4-keto-3-methyl-
2,6-dideoxy-L-glucose (J) to TDP-L-mycarose (K) [12]. EryBV,
which ordinarily transfers the mycarose sugar onto eryth-
ronolide B, is also capable of recognizing 6dEB as a substrate.
Finally, plasmid pHL71 also included E. coli groEL and groES
genes, as they were found to enhance glycosyl transferase
gene expression in earlier studies [22]. As shown below, along
with the genes responsible for desosamine biosynthesis and
transfer, the entire mycarose operon functions efﬁciently in
E. coli BL21(DE3).
Efficiency of Deoxysugar Biosynthesis and Transfer in E.
coli
To assess the metabolic capacity of the desosamine
biosynthesis and transfer pathway in E. coli, BL21(DE3)/
pHL50 was grown in the absence of antibiotics. The IPTG-
induced culture was fed with aMEB (isolated from a mutant
strain of S. erythraea), and the time course of erythromycin D
accumulation was monitored by a B. subtilis inhibition assay
using an authentic sample of erythromycin D as a reference
(Figure S1A). Upon induction with 10 lM IPTG and the
addition of 100 mg/l aMEB at 20 8C, approximately 25%
conversion to erythromycin D was observed (Figure 2).
Consistent with earlier observations [22], the biosynthetic
efﬁciency doubled when GroEL/GroES were coexpressed with
the synthetic desosamine operon.
The cumulative efﬁciency of the mycarose and desosamine
pathways was evaluated in shake-ﬂask studies with E. coli
BL21(DE3)/pHL71/pHL50, using 100 mg/l 6dEB substrate.
After 72 h, the culture supernatant showed activity compa-
rable to 3 mg/l erythromycin D (Figure 2 and Figure S1B).
Because 6-deoxyerythromycins are less active than the
corresponding erythromycins [30,31], the biosynthetic efﬁ-
ciency of the two-sugar pathway was judged to be .10 mg/l.
Macrolide Resistance and Export
Macrolide antibiotics inhibit bacterial cell growth by
binding to the exit tunnel of the 50S ribosomal subunit
[32]. A common resistance mechanism involves ribosome
methylation, which prevents macrolide binding to the
ribosome by introducing steric hindrance in the antibiotic
binding pocket. Although the heterologous expression of the
methylase gene ermE [33] in E. coli BL21(DE3) renders the host
more resistant to erythromycin A in liquid culture (unpub-
lished data), on semisolid plate media the host is not inhibited
by endogenously produced erythromycin in the absence of
ermE. Correspondingly, BL21(DE3)/pHL50 is naturally resist-
ant to aMEB up to 400 mg/l, and ermE was not deemed
necessary in our system.
It is known that endogenous multidrug pumps such as
MacAB [34] and AcrAB [35,36] in E. coli are efﬁcient at
Table 1. Plasmids Used
Plasmid Genes Function Substrate Vector
pHL14 (Kan
R) tylAI-desIV-desI-desII-desV-desVI TDP-desosamine biosynthesis aMEB, aM-6dEB pET
pHL15 (Carb
R) eryCIII-eryCII-fldA-fldR-ermE Desosaminyl transferase and
accessory proteins
aMEB, aM-6dEB
pET
pHL50 (Kan
R) eryCIII-eryCII-tylAI-desIV-desI-desII-desV-desVI TDP-desosamine biosynthesis
and transfer
aMEB, aM-6dEB pET
pHL62 (Kan
R) eryCIII-eryCII-tylAI-desIV-desI-desII-desV-desVI-ermE TDP-desosamine biosynthesis
and transfer
aMEB, aM-6dEB pET
pHL71 (Cm
R) groES-groEL-tylCVII-eryBIV-eryBVI-eryBV-tylCIII-eryBII TDP-mycarose biosynthesis and
transfer þ chaperone
EB, 6dEB pGZ119
pHL74 (Cm
R) eryCIII-eryCII-tylAI-desIV-desI-desII-desV-desVI TDP-desosamine biosynthesis
and transfer
aMEB, aM-6dEB pGZ119
pHL80 (Strep
R) groES-groEL-tylCVII-eryBIV-eryBVI-eryBV-tylCIII-eryBII TDP-mycarose biosynthesis
and transfer þ chaperone
EB, 6dEB pCDF-Duet
pBP130 (Carb
R) debs2-debs3 Biosynthesis of 6dEB Sodium propionate pET
pBP144 (Kan
R) pcc-debs1 Biosynthesis of 6dEB Sodium propionate pET
pBP175 (Kan
R) pcc-mod2 Biosynthesis of 6dEB NDK þ Sodium propionate pET
doi:10.1371/journal.pbio.0050045.t001
Figure 2. Production of 6d-EryD
Blue circles, aMEB conversion to erythromycin D by BL21/pHL50. Red
diamonds, 6dEB conversion to 6d-EryD by BL21/pHL50/pHL71.
Cells were induced at 20 8C with 10 lM IPTG, and samples were collected
72 h after induction. aMEB or 6dEB was added at a final concentration of
100 mg/l. The abscissa (%) indicates the volume of E. coli culture medium
added to LB inoculated with B. subtilis.
doi:10.1371/journal.pbio.0050045.g002
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[34,37]. To test whether aMEB is secreted by BL21/pHL80/
pHL50, we cospotted E. coli strains BL21(DE3)/pHL80/pHL50
(pHL80 is a Strep
R analog of the mycarose plasmid pHL71)
and BL21(DE3)/pHL50 in close proximity on a Petri plate
containing 6dEB. It was anticipated that aMEB secreted by
the former strain would be converted into 6d-EryD by the
latter strain. A dramatic increase in antibiotic activity was
observed around BL21(DE3)/pHL50 (Figure S2). This is
consistent with the observations that monoglycosylation is
efﬁcient, whereas diglycosylation is inefﬁcient (Figure 2). It
also suggests that, while endogenous multidrug resistance
mechanisms in E. coli enable this host to synthesize
erythromycin without self-destruction, they also contribute
to biosynthetic inefﬁciency by prematurely exporting the
mycarosylated precursor.
Production of 6d-EryD in E. coli
To synthesize a bioactive erythromycin in E. coli, the host
strain BAP1 (engineered for the phosphopantetheinyl mod-
iﬁcation of DEBS as well as propionyl-CoA biosynthesis [38])
was cotransformed with plasmids pBP144 (Carb
R, encoding
the DEBS1 and the pccAB genes), pBP130 (Kan
R, encoding for
DEBS2 and DEBS3), pHL74 (a Cm
R analog of the desosamine
plasmid pHL50), and pHL80 (a Strep
R analog of the mycarose
plasmid pHL71). The resulting strain produced low levels of
6d-EryD, detectable by mass spectrometry, but estimated to
be very low. This poor productivity is consistent with an
earlier report of , 1 mg/l glycosylated macrolide production
in E. coli [7]. Indeed, it was not possible to observe bioactivity
from single colonies of this transformant on a Petri plate.
However, as described below, an activity-based screening
assay was developed to enhance the productivity of this
progenitor strain of E. coli.
Bioactivity-Based Screening Assay for 6d-EryD
Overproducers
Although single colonies of E. coli BAP1/pBP144/pBP130/
pHL80/pHL74 were unable to synthesize adequate antibiotic
to generate a halo in a B. subtilis overlay assay, small patches
(;0.5 cm
2) of individual colonies revealed detectable growth
inhibition in an equivalent assay. We therefore tested several
independent transformants via this method and isolated
single colonies of the best two producers by restreaking,
followed by repeated bioassays on small patches derived from
individual colonies. After three rounds of screening, individ-
ual colonies showed a readily observable signal in a B. subtilis
overlay assay (Figure 3A). Two overproducers, mutant A and
mutant B, produced 6d-EryD, comparable to 2 mg/l eryth-
romycin D in shake ﬂask experiments (Figure 3B). Consider-
Figure 3. Screening for 6d-EryD Overproducers
(A) Single-colony screening assay of the Mutant A: B. subtilis inhibition
assay after 60 h.
(B) Shake-flask production of 6d-EryD by mutants, as assayed via B.
subtilis inhibition assay. Comparison of Mutant A versus Mutant B versus
wild-type of strain BAP1/pBP130/pBP144/pHL80/pHL74 after 72 h. Cells
were grown in the presence of 2 g/l propionate, and induced with 0.5
mM IPTG at 30 8C.
doi:10.1371/journal.pbio.0050045.g003
Figure 4. Analysis of the Mechanistic Basis for 6d-EryD Overproduction
by Mutant A
(A) SDS-PAGE analysis of Ni affinity-purified lysates of BL21/pHL80* and
BL21/pHL80 following induction with 0.5 mM IPTG at 30 8C for 5 h.
(B) The relative copy number of pHL80 and pHL80* in E. coli XL1-Blue.
doi:10.1371/journal.pbio.0050045.g004
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erythromycin, we estimated a titer of 5–10 mg/l 6d-EryD
production in shake-ﬂask experiments.
Analysis of 6d-EryD Overproducers
To obtain preliminary insights into the mechanistic basis
for 6d-EryD overproduction in the above mutants, we ﬁrst
compared the stability of each plasmid of a representative
overproducer and the wild-type strain. Although the over-
producer showed marginally improved stability (;23), this
difference could not explain the considerable increase in
antibiotic productivity. Therefore, we puriﬁed each plasmid
from a mutant cell line and retransformed E. coli BAP1 cells
along with the other three wild-type plasmids. Only the
mutant plasmid pHL80* was sufﬁcient to reconstitute the
overproducer phenotype, as judged by single-colony assays
(Figure S3). Restriction analysis of pHL80* showed no
differences relative to pHL80 that would be suggestive of a
subtle mutation. However, comparative protein expression
analysis of BL21(DE3)/pHL80* versus BL21(DE3)/pHL80
showed major differences after 5 h of induction with 0.5
mM IPTG at 30 8C (Figure 4). The mutant pHL80* revealed
more balanced expression of the mycarose biosynthetic and
transfer enzymes compared to pHL80, which selectively
overexpressed the ketoreductases EryBII and EryBIV. Further
analysis revealed that the copy number of pHL80* is
signiﬁcantly lower than pHL80 (15%–20%; Figure 4B). Other
investigators have also observed that lower-copy-number
plasmids can enhance the production of natural products
in bacteria [39]. Presumably, the lower copy number of
pHL80* can reduce the overall burden of heterologous
protein expression in the host cell, although further inves-
tigations are warranted in this regard.
Bioassay-Guided Evolution of Precursor-Directed
Biosynthesis of Antibiotics
Because the plasmid pHL80* signiﬁcantly enhanced mac-
rolide antibiotic biosynthesis in E. coli, we hypothesized it
would also improve the productivity of other related anti-
biotic-producing systems. We therefore introduced pHL80*
and pHL74 into BAP1/pBP130/pBP175, which contains a
deletion of the loading didomain and module 1 of DEBS. The
resulting strain is inherently incapable of polyketide pro-
duction, but does so in the presence of a variety of
exogenously introduced thioester substrates [40]. This meth-
od has been used to prepare a wide range of new macrolide
antibiotics with promising biological activities [41,42]. As
predicted, colonies of BAP1/pBP130/pBP175/pHL80*/pHL74
supplemented with 100 lM( 2 S,3R)-2-methyl-3-hydroxy-pen-
tanoyl-SNAc (NDK) produced 6d-EryD, whereas no signal was
observed with the control strain harboring wild-type plasmids
(BAP1/pBP130/pBP175/pHL80/pHL74) in the B. subtilis inhib-
ition assay. This result demonstrated the utility of pHL80* as
a general toolkit for improving glycosylated macrolide
biosynthesis in E. coli.
Single colonies of E. coli BAP1/pBP130/pBP175/pHL80*/
pHL74 were grown for 48–60 h in the presence of 25 lM, 100
lM, 300 lM, or 1 mM NDK. At substrate concentrations
below 100 lM, halo sizes increased with increasing NDK
concentrations, whereas no further increase in signal was
observed at [NDK] . 100 lM (unpublished data). Therefore,
we screened colonies at a subsaturating NDK concentration
of 25 lM, and isolated mutants (Mutant C, Mutant D) that
exhibited a signiﬁcantly larger halo size (Figure 5A). Shake-
ﬂask comparisons of Mutant C, Mutant D, and wild-type
BAP1/pBP130/pBP175/pHL80*/pHL74 revealed that Mutant
C and Mutant D are more effective than wild-type in
Figure 5. Screening of BAP1/pBP130/pBP175/pHL80*/pHL74 for Mutants (e.g., Mutant C, Mutant D) Capable of Improved Precursor-Directed
Biosynthesis
(A) Single-colony screening assay of BAP1/pBP130/pBP175/pHL80*/pHL74 with 0.5 mg/ml propionate and 100 lM synthetic diketide substrate (NDK).
(B) Kinetics of Mutant C, Mutant D, and wild-type. BAP1/pBP130/pBP175/pHL80*/pHL74 in shake-flask experiments with fixed growth time (48 h), and
with different [NDK].
(C) Kinetics of Mutant C, Mutant D, and wild-type. BAP1/pBP130/pBP175/pHL80*/pHL74 in shake-flask experiments with fixed [NDK] (300 lM), and at
different timepoints.
(In shake-flask experiments, the cultures were induced by adding 0.1 mM IPTG at 30 8C with 2.5 g/l propionate and NDK.)
doi:10.1371/journal.pbio.0050045.g005
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mechanistic basis for this phenotype is under investigation,
this example illustrates the potential for directed evolution in
macrolide biosynthetic engineering.
In conclusion, we have reconstituted the 6d-EryD bio-
synthetic pathway in E. coli, and used it to develop an activity-
based screen for macrolide biosynthesis. Our results repre-
sent the ﬁrst example of the bioassay-guided evolution of an
antibiotic pathway in a heterologous host, thereby opening
the door for harnessing the power of genetics for under-
standing and manipulating polyketide biosynthesis.
Materials and Methods
Construction of plasmids. eryBII, eryBIV, eryBV, eryBVI, eryCII, and
ermE were ampliﬁed from S. erythraea genomic DNA by PCR, using
primers with NdeI and SpeI restriction sites (underlined): eryBIV,
forward, 59-AAAAAACATATGAATGGGATCAGTGATT-
CCCCGCGT-39, reverse, 59-AAAAAAACTAGTGTGCTCCTCGGT-
GGGGGT-39; eryBVI, forward, 59- AAAAAACATATGCGGGTCTTG-
ATCGACAACGCC-39, reverse, 59-AAAAAAACTAGTTCCGGCGGT-
CCTGGTGTA-39; eryBV, forward, 59-AAAAAACATATGCGGGTACT-
GCTGACGTCCTTC-39,r e v e r s e ,5 9-AAAAAAACTAGTGCCGGCG-
TGGCGGCG-39; eryBII, forward, 59-AAAAAACATATGACCACC-
GACGCCGCGAC-39, reverse, 59-AAAAAAACTAGTCTGCAACCAG-
GCTTCCGGC-39; eryCII, forward, 59- AAAAAACATATGACCACGA-
CCGATCGCGCC-39, reverse, 59- AAAAAAACTAGTTCAGAGCTCG-
ACGGGGCA-39; and ermE, forward, 59- AAAAAACATATGAGCAGT-
TCGGACGAGCAGCCG-39,r e v e r s e ,5 9- AAAAAAACTAGTCCGC-
TGCCCGGGTCCGCC-39.
Genes encoding GroEL and GroES were ampliﬁed from E. coli
BL21(DE3) genomic DNA using following primers with NdeI and SpeI
restriction sites (underlined) by PCR: GroES, forward, 59-AAAAAA-
CATATGAATATTCGTCCATTGCATGATCG-39, reverse, 59-AAA-
AAAACTAGTTTACGCTTCAACAATTGCCAGAA-39;a n dG r o E L ,
forward, 59- AAAAAACATATGGCAGCTAAAGACGTAA-
AATTCGGT-39, reverse, 59-AAAAAAACTAGTTTACATCATG-
CCGCCCATGC-39.
Genes encoding tylAI, tylCIII, and tylCVII were ampliﬁed from
genomic DNA of S. fradiae using following primers with restriction
sites (underlined) by PCR: tylAI, forward, 59- AAAAAACATATGAAC-
GACCGTCCCCGCCGC-39,r e v e r s e ,5 9-AAAA AACTCGAGT-
CACTGTGCCCGGCTGTC-39; tylCIII, forward, 59-
AAAAAACATATGCCCGCTGTTCCCCGAGAG-39,r e v e r s e ,5 9-
AAAAAAACTAGTTACGACGTCGAGCCGGGG-39; and tylCVII, for-
ward, 59-AAAAAACATATGATCATCACCGAGACCAGGGTC-39, re-
verse, 59-AAAAAACTCGAGCATGGCCGGATAGGCC  39.
Each PCR product was cloned into pET28 or pET21 vectors. Genes
werecoexpressedassyntheticoperons.Speciﬁcally,eryCIII,eryCII,tylAI,
desIV, desI, desII, desV, and desVI were cloned into a modiﬁed pET28
vector using XbaI and SpeI restriction sites, yielding pHL50. Similarly,
pHL71 was constructed by inserting groEL, groES, tylCVII, eryBIV,
eryBVI, eryBV, tylCIII, and eryBII genes into a modiﬁed pGZ119 vector.
Bacterial strains. For cloning purposes, E. coli XL1-Blue strain was
used. For gene expression, E. coli BL21(DE3) was used. Alternatively,
for the production of 6d-EryD, E. coli BAP1 [38] was cotransformed
with pBP130, pBP144, pHL80, and pHL74.
Conversion of aMEB into erythromycin D. BL21/pHL50 (200 ml)
was grown at 37 8Ct oa nO D 600 ¼ 0.6. The culture was chilled on ice
for 10 min and spun down at 4,000g for 15 min. After washing with
LB, the cell pellet was resuspended in 10 ml of fresh LB without any
antibiotic. To this culture, 100 mg/l aMEB and IPTG was added, and
the cell culture was incubated at 18 8Co r2 08C for 72 h.
Conversion of 6dEB into 6d-EryD. BL21(DE3) cells were cotrans-
formed with pHL50 and pHL71 and grown in the presence of
kanamycin (50 lg/ml) and chloramphenicol (34 lg/ml) at 37 8C. A 100-
ml LB culture was shaken at 200 rpm at 37 8C until OD600 ¼ 0.6. The
culture was chilled on ice for 10 min and cells were harvested by
spinning 10 min at 4,000g. Cells were washed once with 100 ml of ice-
cold LB, resuspended in 5 ml of LB without antibiotics, and induced
with 10 lM IPTG in the presence of 100 lg/ml 6dEB at 20 8C.
B. subtilis inhibition assays. To detect or quantify a glycosylated
macrolide in the spent culture medium of an E. coli strain, a test
sample of the 0.2 lm ﬁltered culture medium was added to a freshly
inoculated culture of B. subtilis. No exogenous antibiotics were used
during the growth of the E. coli culture. The growth rate of B. subtilis,
calculated by measuring OD600 as a function of time, was used to
estimate the amount of macrolide antibiotic. To detect macrolides
produced by single E. coli colonies, LB plates were prepared with 0.5
mg/ml of sodium propionate or other substrates, such as 6dEB or
aMEB, added at appropriate concentrations. A sterilized cellophane
disk soaked with water was placed on top of the LB plate. The test
strain of E. coli was plated on the cellophane disk at an appropriate
cell density. After 2–3 d at 30 8C, the cellophane disk was removed
from the plate, and 2.5 ml of a soft agar overlay containing 0.1% B.
subtilis culture was added to each plate. After overnight growth at 30
8C, halos arising due to growth inhibition of B. subtilis were visualized
around individual colonies.
Biosynthesis of 6d-EryD. E. coli BAP1 cells were cotransformed with
pBP130 (Carb
R), pBP144 (Kan
R), pHL80 (Sm
R), and pHL74 (Cm
R).
Cells were grown in 1 l LB with antibiotics until OD600 ¼ 0.6, and
concentrated in 50 ml of LB in shake-ﬂask as above without any
antibiotics, and induced with 2.5 g/l sodium propionate and 0.1 mM
IPTG at 20 8Co r3 08C.
Analyses of Mutant A. To isolate individual plasmids from the
overproducer Mutant A, a 10-ml LB culture was grown overnight with
kanamycin (50 mg/l), carbenicillin (100 mg/l), chloramphenicol (34
mg/l), and streptomycin (50 mg/l). The cells were centrifuged, and
plasmids were puriﬁed by ethanol precipitation. The puriﬁed plasmid
mixture (1 ll) was transformed to XL1-Blue and spread on LB plates
with each of the four antibiotics present individually. The antibiotic
resistance proﬁles of selected colonies from each plate were screened,
and individual plasmids were puriﬁed from colonies bearing only one
plasmid.
To test the stability of each plasmid, mutant A was grown in LB
with all antibiotics (kanamycin, carbenicillin, chloramphenicol, and
streptomycin), and diluted 10
6-fold. 100-ll aliquots were spread on
plates containing each antibiotic individually. By comparing the
number of colonies on each plate to a control plate with no
antibiotic, the stability of each plasmid was assessed.
To test whether the plasmids in Mutant A had undergone gross
structural changes, appropriate restriction digests were analyzed for
each plasmid (pBP130: XmnI, NotI; pBP144: XhoI, NdeI þ EcoRI;
pHL80: NotI, XhoI; pHL74: SphI, EcoRI). The expected fragments
were veriﬁed by agarose gel electrophoresis.
To evaluate protein expression levels in BL21(DE3)/pHL80* and
BL21(DE3)/pHL80, 100-ml LB cultures with 50 lg/ml streptomycin
were incubated at 37 8C until OD600 ¼ 0.6. The culture was induced
with 0.5 mM IPTG at 30 8C, and allowed to incubate for 5 h. Cells were
harvested by centrifugation at 4,000g, and lysed by sonication. Ni-
NTA afﬁnity puriﬁcation was used for further enrichment of proteins
expressed by plasmid-borne genes.
To analyze the relative copy number of pHL80 and pHL80* in E.
coli, 5-ml LB cultures were grown with 50 lg/ml streptomycin at 37 8C.
After 12 h, cells were harvested, and DNA was extracted using
QIAprep Spin Miniprep Kit (DNA was eluted after 2 min of
incubation with 200 llo f7 08CH 2O; QIAGEN, http://www.qiagen.
com). The amount of DNA was calculated based on the absorbance at
260 nm, and the cell density was calculated by serial dilution. The
relative copy number of a plasmid was measured as the amount of
plasmid DNA per cell.
Precursor-directed biosynthesis with BAP1/pBP130/pBP175/
pHL80(*)/pHL74. The same procedure used in 6dEB or aMEB feeding
experiments was also used in these experiments, except that 2.5 mg/
ml propionate and an appropriate concentration of NDK were added
instead of 6dEB or aMEB. In shake-ﬂask experiments, the culture was
induced by 0.1 mM IPTG at 30 8C.
Supporting Information
Figure S1. Production of 6d-EryD: B. subtilis Growth Inhibition Assay
(A) Calibrating the antibacterial activity of authentic erythromycin D.
(B) 6dEB conversion to 6d-EryD by BL21(DE3)/pHL50/pHL71. Anti-
biotic concentration was measured by a B. subtilis inhibition assay.
Protein expression was induced at 20 8C with 10 lM IPTG, and a
sample was taken 72 h after induction. 6dEB was added at a ﬁnal
concentration of 100 mg/L. The abscissa (%) indicates the volume of
E. coli culture medium added to LB inoculated with B. subtilis.
Found at doi:10.1371/journal.pbio.0050045.sg001 (591 KB TIF).
Figure S2. Bioassay Detection of aMEB Exported from BL21(DE3)/
pHL80/pHL50
A converter strain, BL21(DE3)/pHL50, harboring the desosamine
biosynthetic and transfer genes, was streaked around BL21/pHL80/
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Directed Evolution of AntibioticspHL50 on a plate containing 5 mg/l 6dEB. The B. subtilis overlay test
was performed at 30 8C after 65 h.
Found at doi:10.1371/journal.pbio.0050045.sg002 (9.4 MB TIF).
Figure S3. Analysis of Mutant A: Identiﬁcation of Overproducing
Mutation on pHL80*
(A) Transformants derived from wild-type pBP130, wild-type pBP144,
mutant A–derived pHL80, and mutant A–derived pHL74.
(B) Transformants derived from wild-type pBP130, wild-type pBP144,
mutant A–derived pHL80, and wild-type pHL74.
(C) Transformants derived from wild-type pBP130, wild-type pBP144,
wild-type pHL80, and mutant A–derived pHL74.
The LB plates (with 0.5 mg/ml propionate) were grown at 30 8C for 60
h before being overlaid with the B. subtilis tester strain.
Found at doi:10.1371/journal.pbio.0050045.sg003 (8.7 MB TIF).
Figure S4. LC-MS analysis of 6d-EryD production by BAP1/pBP130/
pBP144/pHL80*/pHL74
The culture was induced with 100 lM IPTG in the presence of 2.5 g/L
propionate at 30 8C for 72 h.
(A) Base peak (positive ion electrospray ionization) full-spectrum
(MW 200–2,000), total ion current (TIC) ¼ 3.72 3 10
7,1lgo f
erythromycin A was added as an external standard.
(B) 6d-EryD, RT (retention time): 15.02–15.20 min, TIC ¼ 1.54 3 10
7.
Found at doi:10.1371/journal.pbio.0050045.sg004 (1.1 MB TIF).
Figure S5. Analysis of 6d-EryD by High-Resolution Mass Spectrom-
etry
(A) Analysis of 6d-EryD from shake-ﬂask cultures of BAP1/pBP130/
pBP144/pHL80/pHL74 Mutant A.
(B) Analysis of 6d-EryD from shake-ﬂask cultures of BL21/pHL50/
pHL71 with 100 mg/l 6dEB.
Found at doi:10.1371/journal.pbio.0050045.sg005 (3.2 MB TIF).
Figure S6. Negative Control Experiments for Glycosylations
Negative controls for the experiments in Figure 2.
Found at doi:10.1371/journal.pbio.0050045.sg006 (862 KB TIF).
Figure S7. Conversion of TDP-Glucose to TDP-4-Keto-6-Deoxy-
Glucose by DesIV
The assays were performed in 100 mM phosphate (pH 8.0), 1 mM DTT,
and 5% glycerol in the presence of 1 mM TDP-D-glucose, 1 mM NAD
þ,
and 8 lM DesIV at 25 8C and monitored by UV detector at 264 nm.
For high-performance liquid chromatography analysis, H2O with
0.1% TFA and acetonitrile with 0.1% TFA were used as buffer A and
buffer B. The gradient program used was 2% buffer B for 2 min, 2%–
16% buffer B for 10 min, and 95% buffer B for 5 min. Alltech Apollo
C18 column, 25 mm 3 4 mm (http://www.alltech.com), was used.
Found at doi:10.1371/journal.pbio.0050045.sg007 (892 KB TIF).
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